Several possible studies
Story checked
FDA approves first gene therapy treatment for Sanfilippo syndrome type A (opens in a new tab)
medicalxpress.com · 2026-09-23
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
FDA approves first gene therapy treatment for Sanfilippo syndrome type A
medicalxpress.com · 2026-09-23
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 5Not checkedThe FDA approved FAYUVI as the first gene therapy treatment for Sanfilippo syndrome type A.View evidenceHide evidence
As statedfirst gene therapy treatment
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 5Not checkedThe FDA approved the treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 5Not checkedKevin Flanigan led the first clinical trial for a systemic gene therapy for this disorder, and he said the first participant was dosed in 2016.View evidenceHide evidence
As statedfirst participant was dosed in 2016
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 5Not checkedSanfilippo syndrome type A is described as the most severe form of Sanfilippo syndrome, affecting the brain and spinal cord and causing progressive developmental and neurological decline in children.View evidenceHide evidence
As statedmost severe form
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 5Not checkedThe article says FAYUVI is an AAV9 gene-replacement therapy that packages the SGSH gene into an adeno-associated virus for intravenous infusion.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref · 15 candidate papers
Assessing the biopotency of the rAAV9 vector In Vitro.
PloS One · 2026 · PubMed
312. Rapid CNS Correction in MPS IIIA Mice Using Systemic Delivery of Self-Complementary AAV9 and AAVrh74 SGSH Vectors
Molecular Therapy · 2012 · Crossref
Systemic scAAV9.U1a.hSGSH Delivery Corrects Brain Biochemistry in Mucopolysaccharidosis Type IIIA at Early and Later Stages of Disease.
Human Gene Therapy · 2021 · PubMed
AAVrh10-SGSH intracerebral gene therapy corrects the defect and improves the health status in mucopolysaccharidosis type IIIa
Molecular Genetics and Metabolism · 2015 · Crossref
Targeting the Root Cause of Mucopolysaccharidosis IIIA with a New scAAV9 Gene Replacement Vector.
Molecular Therapy. Methods & Clinical Development · 2020 · PubMed
And 10 more candidates considered.